The system features a three-pedal foot switch, an optional cooling unit, and an electronically-adjustable patient chair. Credit: Gorodenkoff / Shutterstock.

A German hospital has ordered a Navigated Brain Stimulation (NBS) 5 system, developed by Finnish medical technology company Nexstim.

The Food and Drug Administration (FDA)-approved and CE-marked system comprises a mobile cart, TMS stimulator, stimulation coil and a channel EMG.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A stereotactic camera along with an NBS computer system equipped with dual 23in displays, PC and NBS software are included.

Tracking tools including NBS head tracker, coil tracker and digitising pen are designed for ease of use.

Besides, the system features a three-pedal foot switch, an optional cooling unit, and an electronically-adjustable patient chair.

Its motor and speech mapping features enable the presurgical mapping of cortices of the brain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With therapeutic capabilities, the system can also be used in treating major depression and chronic neuropathic pain.

Nexstim CEO Mikko Karvinen said: “In Germany, we have traditionally seen widespread interest towards our technology among neurosurgical professionals.

“We are happy to have such an established user community including key opinion leaders, and to see that there is continuing demand for combined system solutions in the German market.”

Nexstim’s portfolio also includes a non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS).

Its 3D navigation is claimed to provide accurate and personalised targeting of the TMS to the specific area of the brain.